The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome

Emami, T. and Rezayat, S. M. and Khamesipour, A. and Madani, R. and Habibi, G. and Hojatizade, M. and Jaafari, M. R. (2018) The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome. Artificial Cells, Nanomedicine and Biotechnology, 46 (sup2). pp. 324-333.

[img] Text
The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALBc mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.pdf

Download (2MB)

Abstract

Adjuvants play an essential role in the induction of immunity against leishmaniasis. In this study, monophosphoryl lipid A (MPL) and imiquimod (IMQ) were used as TLR ligands adjuvants to enhance immunogenicity and rate of protection against leishmaniasis. Nanoliposomes containing soluble Leishmania antigens (SLA) and adjuvants were consisted of DSPC, DSPG and Chol prepared by using lipid film method followed by bath sonication. The size of nanoliposomes was around 95 nm and their zeta potential was negative. BALB/c mice were immunized by liposomal formulations of lip/SLA, lip/MPL/SLA, lip/IMQ/SLA, lip/MPL/IMQ/SLA, lip/SLA + lip/IMQ, lip/SLA + lip/MPL, lip/SLA + lip/MPL/IMQ and five controls of SLA, lip/MPL, lip/IMQ, lip/MPL/IMQ and buffer by subcutaneously (SC) injections, three times in 2 weeks intervals. The synergic effect of two adjuvants when they are used in one formulation showed significantly (p <.001) smaller footpad swelling and the lowest parasite burden in lymph node and foot after the challenge. IgG2a in these groups showed the higher titre compared to control groups, which is compatible with the high IFN-γ production and lowest IL-4. Taken together the results indicated that co-delivery of MPL and IMQ adjuvants and antigen in nanoliposome carrier could be an appropriate delivery system to induce cellular immunity pathway against leishmaniasis. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Item Type: Article
Additional Information: Cited By :3 Export Date: 16 February 2020 Correspondence Address: Jaafari, M.R.; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical SciencesIran; email: Jafarimr@mums.ac.ir
Uncontrolled Keywords: imiquimod leishmaniasis MPL Nanoliposome SLA vaccination Immunization Mammals Delivery systems Immune response Liposomal formulation Synergic effects Antigens 1,2 distearoyl sn glycero 3 phospho (1' rac glycerol) 1,2 distearoyl sn glycero 3 phosphocholine cholesterol gamma interferon immunoglobulin G immunoglobulin G1 immunoglobulin G2a interleukin 4 nanoparticle parasite antigen phosphoryl lipid A soluble Leishmania antigen unclassified drug cytokine immunological adjuvant lipid A liposome protozoon antibody animal cell animal experiment animal model animal tissue antibody response antibody titer Article cellular immunity controlled study cytokine production drug potentiation female foot foot pad immunogenicity in vitro study innate immunity lymph node mouse nanoencapsulation nonhuman parasite load particle size promastigote spleen cell swelling zeta potential analogs and derivatives animal Bagg albino mouse chemistry drug effect immunology Leishmania metabolism solubility spleen Adjuvants, Immunologic Animals Antibodies, Protozoan Antigens, Protozoan Cytokines Liposomes Mice Mice, Inbred BALB C
Subjects: QU Biochemistry
QW Microbiology and Immunology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 20 May 2020 08:46
Last Modified: 20 May 2020 08:46
URI: http://eprints.mums.ac.ir/id/eprint/17267

Actions (login required)

View Item View Item